High Levels of Heavy Metals detected in Feathers of an Avian Scavenger Warn of a High Pollution Risk in the Atacama Desert (Chile)

The Atacama Desert represents the highest levels of mining exploitation in Chile, which inexorably results in high levels of pollution. Raptors, and particularly scavengers, have shown their usefulness to evaluate exposure to environmental contaminants in polluted scenarios. In this study, we used primary feathers from a local avian scavenger, turkey vulture Cathartes aura, to evaluate the exposure to cadmium (Cd), lead (Pb), copper (Cu) and zinc (Zn) in two locations from the southern Atacama Desert (coastal and inland) and a third location from the bordering semiarid region, in northern Chile. All metals were detected in all analyzed samples (n = 54). Mean concentrations in Coastal Atacama were 0.68 ± 0.84 ppm for Cd; 1.97 ± 2.01 ppm for Pb; 59.11 ± 80.69 ppm for Cu; and 107.96 ± 51.00 ppm for Zn, while mean concentrations in Inland Atacama were 0.55 ± 0.42 ppm for Cd; 3.37 ± 2.61 ppm for Pb; 91.66 ± 77.74 ppm for Cu; and 214.03 ± 99.08 ppm for Zn. Mean concentrations in Coastal Coquimbo were 0.63 ± 0.69 ppm for Cd; 1.57 ± 0.92 ppm for Pb; 18.09 ± 6.12 ppm for Cu; and 149.37 ± 105.56 ppm for Zn. These differences could be explained by differences on abundance of mining settlements among areas. According to the literature, these values are very high for all metals, exceeding in some cases those values referred as responsible of health disorders in birds. We strongly recommend further research looking at potential adverse effects caused by heavy metal pollution on the health of human and wildlife populations in the southern Atacama Desert.

PI3K activation promotes resistance to eribulin in HER2-negative breast cancer

BACKGROUND

Eribulin is a microtubule-targeting agent approved for the treatment of advanced or metastatic breast cancer (BC) previously treated with anthracycline- and taxane-based regimens. PIK3CA mutation is associated with worse response to chemotherapy in oestrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic BC. We aimed to evaluate the role of phosphoinositide 3-kinase (PI3K)/AKT pathway mutations in eribulin resistance.

METHODS

Resistance to eribulin was evaluated in HER2- BC cell lines and patient-derived tumour xenografts, and correlated with a mutation in the PI3K/AKT pathway.

RESULTS

Eleven out of 23 HER2- BC xenografts treated with eribulin exhibited disease progression. No correlation with ER status was detected. Among the resistant models, 64% carried mutations in PIK3CA, PIK3R1 or AKT1, but only 17% among the sensitive xenografts (P = 0.036). We observed that eribulin treatment induced AKT phosphorylation in vitro and in patient tumours. In agreement, the addition of PI3K inhibitors reversed primary and acquired resistance to eribulin in xenograft models, regardless of the genetic alterations in PI3K/AKT pathway or ER status. Mechanistically, PI3K blockade reduced p21 levels likely enabling apoptosis, thus sensitising to eribulin treatment.

CONCLUSIONS

PI3K pathway activation induces primary resistance or early adaptation to eribulin, supporting the combination of PI3K inhibitors and eribulin for the treatment of HER2- BC patients.

Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial

BACKGROUND

Pembrolizumab has modest activity if used in patients with hormone-receptor-positive (HR+), HER2-negative, previously treated metastatic breast cancer (BC). Our study investigated whether there would be any clinical benefit in combining chemotherapy with pembrolizumab in a similar patient population.

METHODS

This single-arm, phase Ⅱ trial enrolled women aged ≥18 years with HR+, HER2-negative, inoperable, locally recurrent or metastatic BC. Patients were previously treated with hormonal therapy and 1-2 chemotherapy regimens for locally recurrent and/or metastatic BC. On each 21-day cycle, patients received intravenous pembrolizumab 200 mg on day 1 and eribulin 1∙23 mg/m² on days 1 and 8. The primary endpoint was the clinical benefit rate. Analysis of safety and activity was carried out in all patients who met the screening criteria and received at least 1 dose of study treatment. The trial is registered at ClinicalTrials.gov, NCT03222856.

RESULTS

Of the 44 patients enrolled between January 29 and October 17, 2018, clinical benefit was achieved in 25 (56∙8%, 95% confidence interval [CI]: 41∙0-71∙7), objective response in 18 (40∙9%, 95% CI: 26∙3-56∙8), median progression-free survival was 6∙0 months (95% CI: 3∙7-8∙4), and 1-year overall survival was 59∙1% (95% CI: 45∙8-76∙2). The most common treatment-emergent adverse events (AEs) of any grade were neutropenia (20 [45∙5%]), anaemia (17 [38∙6%]), alopecia (19 [43∙2%]), asthenia (19 [43∙2%]), diarrhoea (14 [31∙8%]), fatigue (14 [31∙8%]), and peripheral neuropathy (12 [27∙3%]). Serious AEs occurred in 14 (31∙8%) patients including febrile neutropenia (3 [6∙8%]), neutropenia (2 [4∙5%]), fever (2 [4∙5%]) and peripheral neuropathy (2 [4∙5%]). Immune-related AEs occurred in 11 (25∙0%) patients. One (2∙3%) patient died of cardiac arrest unrelated to study treatment.

CONCLUSION

Pembrolizumab plus eribulin demonstrates encouraging antitumour activity in patients with heavily pre-treated, HR+, HER2-negative, locally recurrent or metastatic BC. The safety and tolerability of the combination is similar to eribulin or pembrolizumab monotherapy.

Per- and polyfluoroalkyl substances in plasma and feathers of nestling birds of prey from northern Norway

Plasma samples from nestlings of two top predators, White-tailed eagle (Haliaeetus albicilla) and Northern goshawk (Accipiter gentilis) from northern Norway were analysed for a wide range of per- and polyfluoroalkyl substances (PFASs). Body feathers from the White-tailed eagles were also analysed and significant associations between specific PFASs in blood plasma and body feathers were found (0.36 <R² < 0.67; all p < 0.05). This result suggests that analysing body feathers of White-tailed eagle could potentially be a useful non-invasive strategy to monitor PFASs exposure in nestlings of this species. White-tailed eagles showed significantly higher levels of contaminants than Northern goshawks (plasma ∑PFASs Median = 45.83 vs 17.02ngmL^-1, p <0.05). The different exposure between both species seemed to be related to different dietary input, as quantified by stable carbon and nitrogen isotope analysis of body feathers. A priori, the bird of prey populations studied are not at risk for PFASs, since the levels in plasma of both species were hundreds to thousand times lower than the toxic reference values reported for predatory birds. However, further studies on larger sample sizes are needed to confirm this hypothesis since toxic thresholds for nestling birds of prey are not established.

Abstract P5-08-06: PI3K blockade enhances the antitumor activity of eribulin in PIK3CA-mutant eribulin-resistant tumor xenografts

Eribulin is a recently approved microtubule-targeting agent (MTA) for the management of heavily pretreated metastatic breast cancer (BC) patients. Constitutive PI3K/Akt/mTOR survival pathway activation, either via mutational activation of the PI3K catalytic subunit (PIK3CA) or via inactivation of the tumor suppressor PTEN, may confer resistance to MTAs. Hence, we hypothesized that PI3K-pathway activation limits the antitumor activity of eribulin in HER2-negative BC and that PI3K inhibition enhances the efficacy of this chemotherapeutic agent.

The predictive value of PIK3CA mutation or PTEN loss towards eribulin response was interrogated in vitro, using a panel of fourteen HER2-negative BC cell lines, and in vivo using six tumor models from cell-line or patient-derived tumors. While PIK3CA mutation did not seem to be predictive in vitro, the PIK3CA-mutated xenograft models underwent tumor progression upon single-agent eribulin therapy (Table 1). In the absence of concomitant PIK3CA mutation, PTEN loss was neither predictive in vitro nor in vivo. Moreover, eribulin induced PI3K-pathway activation in tumor xenografts, a potential escape mechanism to MTA-therapy. To validate the negative predictive value of PIK3CA mutation, BC tumors from patients treated with eribulin in the neoadjuvant and in the metastatic setting are being queried, as the pharmacodynamic activation of the PI3K-pathway upon eribulin treatment.

Class I pan-PI3K (BKM120) or PI3K-a-specific (BYL719) inhibitors were used in vitro to block the PI3K-pathway concomitantly with eribulin treatment, resulting in enhanced antiproliferative and proapoptotic activity. Strikingly, in PIK3CA mutant xenograft models, while eribulin alone exhibited limited antitumor activity compared to PIK3CA-wild type models, co-administration of a PI3K inhibitor induced marked tumor regression (BKM120 data in Table 1, BYL719 data will be reported). Moreover, addition of the PI3K inhibitor at progression with eribulin single-agent also resulted in tumor regression. Of note, PIK3CA-wild type models also exhibited increased antitumor activity with the combined therapy compared to single-agent treatments. The precise mechanism by which the combination of eribulin and a PI3K-targeting agent results in tumor regression is currently under investigation, embracing both the induction of mitotic catastrophe in tumor cells and the regularization of the tumor vasculature.

These results support the clinical development of therapeutic regimens combining PI3K-inhibitors to the approved MTA eribulin and might be predictive of clinical benefit both in the PIK3CA-mutant and -wild type breast cancer population.

Table 1. Percentage change in tumor volume.StatusPIK3CA mutantPIK3CA mutant and PTEN-lowPTEN-lowWTModel/ TreatmentMCF7LPDX44CAL51MDA-MB-468PDX88PDX98Eribulin39 ± 9683 ± 51364 ± 127-47 ± 14-26 ± 34-36 ± 33BKM120501 ± 169116 ± 111119 ± 73-9 ± 23128 ± 3787 ± 112Eribulin + BKM120-70 ± 27-80 ± 1051 ± 46-75 ± 12-94 ± 5-65 ± 13Patient- (PDX) and cell line-derived tumor xenografts were treated with eribulin mesylate (0.1mg/kg, 3IW) and/or BKM120 (27.5 mg/kg, 6IW) for 26-31 days.. IW, in week.

Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-08-06.

Design of splints based on the NiTi alloy for the correction of joint deformities in the fingers

BACKGROUND

The proximal interphalange joint (PIP) is fundamental for the functional nature of the hand. The contracture in flexion of the PIP, secondary to traumatisms or illnesses leads to an important functional loss. The use of correcting splints is the common procedure for treating this problem. Its functioning is based on the application of a small load and a prolonged stress which can be dynamic, static progressive or static serial.It is important that the therapist has a splint available which can release a constant and sufficient force to correct the contracture in flexion. Nowadays NiTi is commonly used in bio-engineering, due to its superelastical characteristics. The experience of the authors in the design of other devices based on the NiTi alloy, makes it possible to carry out a new design in this work--the production of a finger splint for the treatment of the contracture in flexion of the PIP joint.

METHODS

Commercial orthosis have been characterized using a universal INSTRON 5565 machine. A computational simulation of the proposed design has been conducted, reproducing its performance and using a model "ad hoc" for the NiTi material. Once the parameters have been adjusted, the design is validated using the same type of test as those carried out on commercial orthosis.

RESULTS AND DISCUSSION

For commercial splint the recovering force falls to excessively low values as the angle increases. Angle curves for different lengths and thicknesses of the proposed design have been obtained, with a practically constant recovering force value over a wide range of angles that vary between 30° and 150° in every case. Then the whole treatment is possible with only one splint, and without the need of progressive replacements as the joint recovers.

CONCLUSIONS

A new model of splint based on NiTi alloy has been designed, simulated and tested comparing its behaviour with two of the most regularly used splints. Its uses is recommended instead of other dynamic orthosis used in orthopaedics for the PIP joint. Besides, its extremely simple design, makes its manufacture and use on the part of the specialist easier.

Design of a suture anchor based on the superelasticity of the Ni-Ti alloy

We have designed and manufacture a prototype of a new anchoring system for soft bone tissue fixation, based on the superelasticity of the Ni-Ti alloy. The anchoring capability has been observed in femoral hips by radiographs. The performance of this new anchor have been measured by tensile experiments and contrasted with finite element model. The results point out that keeping the fixation capacity, the new configuration presents advantages concerning to a minor damaged volume bone, a reduction of the manufacture cost and a simpler insertion.